Keiko Igaki
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
Journal: Journal of neuroimmunology
Published: May 29, 2019
Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: January 10, 2019
Malt1 inactivation attenuates experimental colitis through the regulation of Th17 and Th1/17 cells.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: August 21, 2018
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
Journal: Journal of medicinal chemistry
Published: March 07, 2018
MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model.
Journal: International immunopharmacology
Published: February 08, 2018
Role of Malt1 protease activity in pathogenesis of inflammatory disorders mediated by FcγR signaling.
Journal: International immunopharmacology
Published: November 14, 2017
Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Journal: Biochemical pharmacology
Published: November 14, 2017
Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice.
Journal: International immunopharmacology
Published: August 31, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026